BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:The first wave of investment in NASH is dispersing in the wake
  of highly demanding biopsy endpoints\, but opportunities to target obesi
 ty and metabolic syndrome are catalyzing increasing excitement. Pivotal r
 eadouts in GLP-1 receptor agonists and exciting progress in regenerative 
 medicine and microRNAs are redefining the drug development landscape for 
 metabolic disorders.\n\nWith mounting competition for the market in obesi
 ty and all eyes on the next wave of NASH candidates\, the 6th Obesity and
  NASH Drug Development Summit\, (previously the NASH Summit) is dedicated
  to reuniting industry leaders in metabolic syndrome to consolidate targe
 ts directly implicated in disease pathology and traverse the regulatory h
 urdles to commercialization.\n\nJoin 150+ industry pioneers in Boston inc
 luding pioneers Novo Nordisk\, Eli Lilly\, Boehringer Ingelheim\, Pfizer\
 , Inventiva\, Regeneron\, FDA\, AstraZeneca\, and more to advance your pi
 peline towards approved treatment.\n
DTEND:20221201T164000
DTSTAMP:20260311T192101Z
DTSTART:20221129T095500
LOCATION:Revere Hotel Boston Common\, 200\, Stuart Street\, Boston\, Massa
 chusetts\, 02116\,
SEQUENCE:0
SUMMARY:The first wave of investment in NASH is dispersing in the wake of 
 highly demanding biopsy endpoints\, but opportunities to target obesity a
 nd metabo...
UID:1b74195f-2f55-4f74-a1a7-d6ef2721956c
END:VEVENT
END:VCALENDAR